Please login to the form below

Not currently logged in
Email:
Password:

John LaMattina joins Frequency Therapeutics in advisory role

The ex-Pfizer R&D head will sit on its Scientific Advisory Board

John LaMattinaFrequency Therapeutics has appointed John LaMattina as its senior advisor to the CEO in a role that will see him focus on assisting its development of a treatment for hearing loss, serving on the firm’s Scientific Advisory Board.

LaMattina was previously president of Pfizer’s Global Research and Development department and senior vice president and spent 30 years at the pharma company.

He said: “It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss.

“The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new-disease modifying therapies for hearing and other areas throughout the body.”

Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.

David Lucchino, president, co-founder and CEO of Frequences Therapeutics, said: “As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise.

"John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”

4th April 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics